Successful early regression of giant pulmonary artery aneurysms in Behçet's disease treated with mycophenolate mofetil: A case report

Read full text Summarise with VIRAT
Authors: abdalrhman alras, Khalid Wissam Abdulfattah Khattab, Abdullah Alfandi, Ali Jumaa, Mohammad Adi, Samar Almoazen, Tasneem Alras, Yaman Alsharef, Aiman Abo Al Shamat
Cited by: 0
References: 11

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Pulmonary artery aneurysms are a rare but life-threatening manifestation of Behçet’s disease and are associated with a high risk of fatal hemoptysis. Standard treatment typically involves high-dose corticosteroids combined with cyclophosphamide; however, concerns regarding long-term toxicity and fertility preservation have prompted interest in alternative immunosuppressive strategies. We report the case of a 20-year-old male who presented with recurrent hemoptysis and systemic inflammatory features and was diagnosed with Behçet’s disease complicated by multiple pulmonary artery aneurysms. Computed tomography pulmonary angiography demonstrated several saccular aneurysms, the largest measuring 52 mm in the right lower-lobe pulmonary artery with partial mural thrombosis. The patient was treated with high-dose corticosteroids followed by oral prednisone in combination with mycophenolate mofetil. At four-week follow-up, inflammatory markers had normalized, and repeat imaging demonstrated regression of the aneurysm sizes without new vascular complications.The patient remained clinically stable and was scheduled for further imaging and rheumatology evaluation at two months. This case highlights mycophenolate mofetil as a potential steroid-sparing immunosuppressive option for pulmonary artery aneurysms in Behçet’s disease. • Giant pulmonary artery aneurysms can complicate Behçet’s disease. • Early hemoptysis may signal life-threatening vascular involvement. • Mycophenolate mofetil was used as a steroid-sparing agent. • Rapid radiological regression was observed within four weeks. • Cyclophosphamide toxicity concerns influenced treatment choice.

Fields of Study & Subjects

Ocular Diseases and Behçet’s Syndrome Sarcoidosis and Beryllium Toxicity Research Vasculitis and related conditions

Publication details

Journal / source
Respiratory Medicine Case Reports
Volume
61
Pages
102415–102415
Publication date
1 January 2026
Language
EN